6L8 Stock Overview Operates as a novel bioelectric medicine company. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Pulse Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Pulse Biosciences Historical stock prices Current Share Price US$18.60 52 Week High US$20.00 52 Week Low US$6.15 Beta 1.84 1 Month Change 7.51% 3 Month Change 20.00% 1 Year Change 106.67% 3 Year Change 64.60% 5 Year Change 47.62% Change since IPO -10.84%
Recent News & Updates
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium Jan 21
Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer Jan 10
Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association Nov 01
Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology Oct 31
Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 21 Pulse Biosciences, Inc. announced delayed 10-Q filing Aug 16
See more updates
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium Jan 21
Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer Jan 10
Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association Nov 01
Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology Oct 31
Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 21 Pulse Biosciences, Inc. announced delayed 10-Q filing Aug 16
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors Aug 13
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Aug 08
Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 30
Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million. Jul 16 Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Jul 08 Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc Jun 10
President & CEO recently bought €79k worth of stock May 26 Pulse Biosciences, Inc Announces CEO Changes
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System May 10
New major risk - Financial position May 09
New major risk - Financial position May 08
Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 26
Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024 Apr 24
Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 15
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System Mar 09
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp Jan 02
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter Dec 20
Executive Chairman recently bought €1.0m worth of stock Dec 03
Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode Nov 22
Chief Strategy Officer recently bought €97k worth of stock Nov 18
Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Oct 31
Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery Oct 25
New major risk - Revenue and earnings growth Aug 15
Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer May 06
Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer Dec 07
Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
Chief Strategy Officer & Director recently bought €72k worth of stock Oct 13 Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions Oct 07
Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia Sep 27 Pulse Biosciences, Inc. Announces Executive Changes
Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System Aug 05
Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index Jun 26 Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million. Jun 11
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc Apr 08
Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022 Apr 02
Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022 Mar 23
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc Feb 18
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer Feb 16
Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission Feb 09
Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021 Jan 12
Forecast to breakeven in 2024 Jan 01
Independent Chairman of the Board recently bought €42m worth of stock Jul 05
Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada Jul 01
Pulse Biosciences Announces Health Canada Approval for CellFX® System Jun 10
Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference May 14
Pulse Biosciences Announces First CellFX Procedures Feb 20
Pulse Biosciences Announces Start of Controlled Launch of the CellFX System® Feb 18
Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021 Feb 13
Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System Feb 04
New 90-day high: €23.60 Jan 22
Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress Jan 13
New 90-day high: €19.30 Jan 04
New 90-day high: €15.20 Dec 04
Pulse Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Oct 29
Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery Virtual Annual Meeting Oct 08
Pulse Biosciences, Inc. Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study Oct 03
Pulse Biosciences, Inc. Announces the Company Is Not Reasonably Estimate the Future Impact to the Operations and Financial Results Aug 11 Shareholder Returns 6L8 DE Medical Equipment DE Market 7D 12.7% 5.1% 2.3% 1Y 106.7% -1.3% 11.9%
See full shareholder returns
Return vs Market: 6L8 exceeded the German Market which returned 13.2% over the past year.
Price Volatility Is 6L8's price volatile compared to industry and market? 6L8 volatility 6L8 Average Weekly Movement 14.0% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6L8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6L8's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Show more Pulse Biosciences, Inc. Fundamentals Summary How do Pulse Biosciences's earnings and revenue compare to its market cap? 6L8 fundamental statistics Market cap €1.16b Earnings (TTM ) -€44.30m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6L8 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$46.13m Earnings -US$46.13m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/22 18:31 End of Day Share Price 2025/01/22 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pulse Biosciences, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Swayampakula Ramakanth H.C. Wainwright & Co. Anthony Vendetti Maxim Group Christopher Cooley Stephens, Inc.
Show 0 more analysts 
